Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Journal of Clinical Oncology|2022Cited by 331
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaRobert J. Kreitman, Francis J. Giles, Claire Dearden et al.|Leukemia|2018Cited by 250
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphomaOlalekan O. Oluwole, Tom van Meerten, Krimo Bouabdallah et al.|British Journal of Haematology|2021Cited by 217
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphomaCharles Herbaux, Franck Morschhauser, Jordan Gauthier et al.|Blood|2017Cited by 217
Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TCCharles Herbaux, Franck Morschhauser, Jordan Gauthier et al.|Blood|2015Cited by 36